Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: Implications for diagnostic microdosing

Gregory T. Wurz, Michael W. DeGregorio

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

As Phase 0 studies have proven to be reasonably predictive of therapeutic dose pharmacokinetics, the application of microdosing has expanded into metabolism, drug-drug interactions and now diagnostics. One potentially serious issue with this application of microdosing that has not been previously discussed is the possibility of activating cellular mechanisms of drug resistance. Here, we provide an overview of Phase 0 microdosing and drug resistance, with an emphasis on cisplatin resistance, followed by a discussion of the potential for inducing acquired resistance to platinum-based or other types of chemotherapy in cancer patients participating in Phase 0 diagnostic microdosing studies. A number of alternative approaches to diagnostic microdosing, such as the human tumor cloning assay and the use of peripheral blood mononuclear cells as a surrogate for measuring DNA adducts, are discussed that would avoid exposing cancer patients to low doses of first-line chemotherapy and the possible risk of triggering cellular mechanisms of acquired resistance. Until it has been established that diagnostic microdosing in cancer patients poses no risk of acquired drug resistance, such studies should be approached with caution.

Original languageEnglish (US)
Pages (from-to)1485-1493
Number of pages9
JournalInternational Journal of Cancer
Volume136
Issue number7
DOIs
StatePublished - Apr 1 2015

Fingerprint

Drug Resistance
Drug Therapy
Neoplasms
DNA Adducts
Platinum
Drug Interactions
Cisplatin
Organism Cloning
Blood Cells
Pharmacokinetics
Pharmaceutical Preparations
Therapeutics

Keywords

  • Acquired resistance
  • Lung cancer
  • Microdosing
  • Platinum-based chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy : Implications for diagnostic microdosing. / Wurz, Gregory T.; DeGregorio, Michael W.

In: International Journal of Cancer, Vol. 136, No. 7, 01.04.2015, p. 1485-1493.

Research output: Contribution to journalArticle

@article{a06a67eaa17d4c98b807f2ab5099f445,
title = "Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: Implications for diagnostic microdosing",
abstract = "As Phase 0 studies have proven to be reasonably predictive of therapeutic dose pharmacokinetics, the application of microdosing has expanded into metabolism, drug-drug interactions and now diagnostics. One potentially serious issue with this application of microdosing that has not been previously discussed is the possibility of activating cellular mechanisms of drug resistance. Here, we provide an overview of Phase 0 microdosing and drug resistance, with an emphasis on cisplatin resistance, followed by a discussion of the potential for inducing acquired resistance to platinum-based or other types of chemotherapy in cancer patients participating in Phase 0 diagnostic microdosing studies. A number of alternative approaches to diagnostic microdosing, such as the human tumor cloning assay and the use of peripheral blood mononuclear cells as a surrogate for measuring DNA adducts, are discussed that would avoid exposing cancer patients to low doses of first-line chemotherapy and the possible risk of triggering cellular mechanisms of acquired resistance. Until it has been established that diagnostic microdosing in cancer patients poses no risk of acquired drug resistance, such studies should be approached with caution.",
keywords = "Acquired resistance, Lung cancer, Microdosing, Platinum-based chemotherapy",
author = "Wurz, {Gregory T.} and DeGregorio, {Michael W.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/ijc.28773",
language = "English (US)",
volume = "136",
pages = "1485--1493",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy

T2 - Implications for diagnostic microdosing

AU - Wurz, Gregory T.

AU - DeGregorio, Michael W.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - As Phase 0 studies have proven to be reasonably predictive of therapeutic dose pharmacokinetics, the application of microdosing has expanded into metabolism, drug-drug interactions and now diagnostics. One potentially serious issue with this application of microdosing that has not been previously discussed is the possibility of activating cellular mechanisms of drug resistance. Here, we provide an overview of Phase 0 microdosing and drug resistance, with an emphasis on cisplatin resistance, followed by a discussion of the potential for inducing acquired resistance to platinum-based or other types of chemotherapy in cancer patients participating in Phase 0 diagnostic microdosing studies. A number of alternative approaches to diagnostic microdosing, such as the human tumor cloning assay and the use of peripheral blood mononuclear cells as a surrogate for measuring DNA adducts, are discussed that would avoid exposing cancer patients to low doses of first-line chemotherapy and the possible risk of triggering cellular mechanisms of acquired resistance. Until it has been established that diagnostic microdosing in cancer patients poses no risk of acquired drug resistance, such studies should be approached with caution.

AB - As Phase 0 studies have proven to be reasonably predictive of therapeutic dose pharmacokinetics, the application of microdosing has expanded into metabolism, drug-drug interactions and now diagnostics. One potentially serious issue with this application of microdosing that has not been previously discussed is the possibility of activating cellular mechanisms of drug resistance. Here, we provide an overview of Phase 0 microdosing and drug resistance, with an emphasis on cisplatin resistance, followed by a discussion of the potential for inducing acquired resistance to platinum-based or other types of chemotherapy in cancer patients participating in Phase 0 diagnostic microdosing studies. A number of alternative approaches to diagnostic microdosing, such as the human tumor cloning assay and the use of peripheral blood mononuclear cells as a surrogate for measuring DNA adducts, are discussed that would avoid exposing cancer patients to low doses of first-line chemotherapy and the possible risk of triggering cellular mechanisms of acquired resistance. Until it has been established that diagnostic microdosing in cancer patients poses no risk of acquired drug resistance, such studies should be approached with caution.

KW - Acquired resistance

KW - Lung cancer

KW - Microdosing

KW - Platinum-based chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84920952992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920952992&partnerID=8YFLogxK

U2 - 10.1002/ijc.28773

DO - 10.1002/ijc.28773

M3 - Article

C2 - 24510760

AN - SCOPUS:84920952992

VL - 136

SP - 1485

EP - 1493

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -